Clinical Utility Study demonstrates PromarkerD test benefits

We are pleased to announce that a study demonstrating the clinical utility of the PromarkerD test in predicting diabetic kidney disease was published today in the journal PLOS ONE. PLOS ONE is a highly regarded peer-reviewed open access journal published by the Public Library of Science (PLOS), publishing primary research across science and medicine.

The publication provides important peer-reviewed validation and recognition of our initial results that we previously presented at major industry conferences.

The clinical utility study forms an important part of the Proteomics International’s ongoing strategy for the roll-out of PromarkerD in the United States. The publication will support the Company’s application for a Proprietary Laboratory Analyses (PLA) reimbursement code, which is necessary for the broad reimbursement of the PromarkerD test by insurance companies and other payors in the US.

ASX Release

PLOS ONE Publication


  • This field is for validation purposes and should be left unchanged.